15/03/2019 06:38:46

“Novaturas“ turnover in February 2019

In February 2019 “Novaturas” turnover was EUR 10.1 million and was 21% higher compared to February 2018.

2019 cumulative “Novaturas” turnover (for January-February period) was EUR 19.4 million and was 23% higher compared to the same period in 2018.

In February 2019, “Novaturas” served 13.4 thousand clients and it was 12% more compared to February 2018. From the beginning of 2019 “Novaturas” has already served 27.6 thousand clients and it was 19% more than in the same period of 2018.

Finance director,

Tomas Staškūnas

tomas.staskunas@novaturas.lt

, +370 687 10426

ntu.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Jun
 
I øjeblikket sidder "vinderne" ved folketingsvalget og forhandler regeringsgrundlag. De er enige om ..
44
18 Jun
 
Ingen grund til at flytte, de fleste har ikke råd, det er altid middelklassen det rammer og alligeve..
34
20 Jun
 
Måske jeg er den eneste, men savner Alpehue og hans gode indlæg... er han her under et andet alias? ..
23
23 Jun
 
Kære Nets-formand, du er i Danmark, ikke USA Vi er et samfund, hvor få har for meget og færre for li..
20
21 Jun
VELO
Mangel på to tacrolimus - konvertere pat. til Envarsus   I USA konvertere de patienter til Envarsus ..
20
21 Jun
 
@ckt - synes egentlig det havde vaeret bedre, du ikke havde skrevet noget overhovedet..
20
19 Jun
OMXC25
  De vil aldrig få penge nok. Jeg vil tro, at der aldrig er tilført de offentlige kasser flere penge..
20
20 Jun
CHEMM
ChemoMetec opjusterer forventningerne til omsætningen og driftsresultatet som følger af højere forve..
19
21 Jun
VELO
Ser ud til at man omkring 1 juli starter et nyt forsøg op med Envarsus hvor man tilsyneladende forve..
17
18 Jun
AMBU-B
Jeg er rigtig tilfred med de udmeldinger JJG kommer med idag. Det giver ro over deres udmeldinger, o..
17

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
OSE Immunotherapeutics Will Participate in HealthTech Investor Days (HTID)
2
Global Arena Holding Inc. (GAHC), Files First Quarter 10Q, and Updates Shareholders on Subsidiaries
3
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Eros International Plc (NYSE: EROS) and Encourages Eros Investors to Contact the Firm
4
Hofseth Biocare ASA: Signed Letter of Intent with Garden of Life® for exclusive use of CollaGo® and ProGo® in the US market
5
Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2019 23:29:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB2 - 2019-06-25 00:29:41 - 2019-06-24 23:29:41 - 1000 - Website: OKAY